I-Smads in Periodontitis

Bulent Ecevit University40 enrolled

Overview

Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Periodontitis Treatment Adherence

Interventions

Periodontally healthy groupDIAGNOSTIC_TEST

probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium

Eligibility

Sex: ALLMin age: 25 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Have at least 20 natural teeth, excluding third molars. * Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. * Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss Exclusion Criteria: * History of systemic disease. * Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. * Periodontal treatment during last 6 months that could affect periodontal status. * Smoking. * History of radiotherapy or chemotherapy. * Current pregnancy, lactation or menopause.

Outcomes

Primary Outcomes

TGF-β, Smad6, and Smad7 levels

the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva

Time frame: baseline

Secondary Outcomes